Cannara Biotech (LOVE) AI Stock Analysis

• Market Cap: C$173.66M
• Dividend Yield: N/A
• Average Volume (3M): 45.69K
• Price to Earnings (P/E): 12.7
• Beta (1Y): 0.22
• Revenue Growth: 30.64%
• EPS Growth: 101.12%
• Country: CA
• Employees: 461
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.04
• Shares Outstanding: 94,895,900
• 10 Day Avg. Volume: 37,006
• 30 Day Avg. Volume: 45,690
• PEG Ratio: 0.00
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 73 Outperform
• Price Target: C$2.00 ▲(9.29% Upside)

Cannara Biotech's strong financial performance and positive corporate events are the most significant factors driving the score. Technical analysis and valuation are neutral, indicating a balanced outlook. The absence of earnings call data does not impact the overall score.

Positive Factors

Revenue Growth

Cannara Biotech's substantial revenue growth of over 30% year-over-year indicates strong market demand and effective sales strategies, supporting long-term business expansion.

Market Share Expansion

Significant market share gains demonstrate Cannara's competitive positioning and ability to capture consumer loyalty, enhancing its market leadership in the cannabis sector.

Operational Expansion

Expanding cultivation capacity by 100% over four years positions Cannara for future growth, increasing production capabilities to meet rising demand.

Negative Factors

Free Cash Flow Concerns

Declining free cash flow growth could hinder Cannara's ability to reinvest in operations and manage debt, potentially impacting long-term financial health.

Debt Management

Using equity to settle debt may dilute existing shareholders and indicates potential challenges in managing leverage, affecting financial stability.

Leadership Change

The loss of a key board member could impact strategic direction and leadership continuity, posing risks to Cannara's governance and decision-making processes.

Cannara Biotech Business Overview & Revenue Model

Company Description

Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-derivated products in Canada. It also offers hemp-based CBD products through e-commerce platform. The company was incorporated in 2017 and is headquartered in Saint-Laurent, Canada.

How the Company Makes Money

Cannara Biotech generates revenue through multiple streams, primarily by selling its cannabis products to retail dispensaries and directly to consumers through its online platform. The company benefits from the growing legalization of cannabis in various jurisdictions, allowing it to expand its market reach. Key revenue streams include wholesale distribution to licensed retailers, direct sales through e-commerce, and potential partnerships with other cannabis companies for co-branding and product development. Additionally, Cannara's focus on quality and compliance with regulatory standards enhances its marketability and pricing power, contributing to its overall profitability.

Cannara Biotech Financial Statement Overview

Summary

Cannara Biotech exhibits strong financial performance with impressive revenue growth and profitability. The balance sheet is stable with a prudent approach to leverage, though attention is needed on improving free cash flow growth.

Income Statement

Cannara Biotech has demonstrated strong revenue growth over the years, with a notable increase in total revenue from 2024 to 2025. The company maintains healthy gross and net profit margins, indicating efficient cost management and profitability. The EBIT and EBITDA margins are also robust, reflecting operational efficiency. Overall, the income statement shows a positive growth trajectory and profitability.

Balance Sheet

The balance sheet reveals a stable financial position with a manageable debt-to-equity ratio, indicating a balanced approach to leveraging. The return on equity has improved over the years, showcasing effective use of equity to generate profits. The equity ratio is strong, suggesting a solid capital structure. However, the company should continue to monitor its debt levels to maintain financial stability.

Cash Flow

Cannara Biotech's cash flow statement shows a positive operating cash flow, which is a good indicator of the company's ability to generate cash from its operations. However, the free cash flow growth rate has declined recently, which could be a concern if it continues. The operating cash flow to net income ratio is healthy, but the company should focus on improving free cash flow to ensure long-term financial health.

Breakdown	TTM	Dec 2025	Dec 2025	Dec 2024	Dec 2023	Dec 2022
Income Statement
Total Revenue	107.62M	―	107.32M	81.75M	57.26M	35.84M
Gross Profit	47.52M	―	47.22M	29.79M	27.23M	17.33M
EBITDA	28.39M	―	28.18M	15.16M	15.77M	9.54M
Net Income	13.08M	―	13.08M	6.44M	6.95M	2.31M
Balance Sheet
Total Assets	168.65M	―	168.65M	154.72M	141.52M	125.62M
Cash, Cash Equivalents and Short-Term Investments	14.36M	―	14.36M	6.62M	4.27M	12.11M
Total Debt	41.58M	―	41.58M	48.33M	45.78M	48.39M
Total Liabilities	66.43M	―	66.43M	66.77M	61.78M	58.88M
Stockholders Equity	102.22M	―	102.22M	87.95M	79.74M	66.74M
Cash Flow
Free Cash Flow	12.82M	―	13.65M	3.21M	-4.44M	-21.55M
Operating Cash Flow	19.18M	―	20.01M	10.68M	5.44M	-6.08M
Investing Cash Flow	-5.95M	―	-5.95M	-5.19M	-9.48M	-15.35M
Financing Cash Flow	-6.32M	―	-6.32M	-3.14M	-3.72M	25.46M

Cannara Biotech Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.83
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:LOVE, the sentiment is Positive. The current price of 1.83 is above the 20-day moving average (MA) of 1.76, above the 50-day MA of 1.71, and above the 200-day MA of 1.59, indicating a bullish trend. The MACD of 0.03 indicates Negative momentum. The RSI at 62.57 is Neutral, neither overbought nor oversold. The STOCH value of 89.47 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:LOVE.

Cannara Biotech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LOVE	73 Outperform	C$173.66M	12.73	13.39%	―	30.64%	101.12%
XLY	67 Neutral	C$198.22M	4.23	31.46%	―	27.38%	―
OGI	54 Neutral	C$321.31M	-11.72	-7.93%	―	62.15%	60.50%
GRIN	52 Neutral	C$154.74M	16.67	15.32%	―	-18.30%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
JUSH	47 Neutral	C$163.26M	-1.77	―	―	3.17%	-24.07%
CBST	37 Underperform	C$227.80M	-1.07	―	―	-26.73%	-32.33%

Cannara Biotech Corporate Events

Cannara Biotech Takes Top Market Share in Québec and Cleans Up Equity Compensation Plans

Cannara Biotech has rapidly emerged as a leading player in Québec’s cannabis market, achieving an estimated 29.7% share of the province’s nascent vape cartridge category and securing the number one overall cannabis retail market share position in Québec for December 2025 with a 14.7% share. Management credits the company’s vertically integrated platform and premium product lineup—particularly its live resin and first-ever rosin vape cartridges—for driving strong initial consumer demand and reinforcing Cannara’s positioning as Canada’s top premium vape producer. Separately, the company addressed an administrative oversight in its equity compensation plans by cancelling and reissuing 544,600 previously granted stock options, including those held by directors and officers, without increasing the total number of options outstanding, and is seeking shareholder approval to convert its rolling stock option and RSU plans into fixed security-based plans to enhance governance, administrative clarity and ongoing compliance with plan limits.

The most recent analyst rating on (TSE:LOVE) stock is a Buy with a C$2.00 price target. To see the full list of analyst forecasts on Cannara Biotech stock, see the TSE:LOVE Stock Forecast page.

Cannara Biotech Achieves Record Fiscal 2025 Performance and Market Expansion

Cannara Biotech Inc. reported record financial performance for Fiscal 2025, with net revenues reaching $107.3 million and achieving its first year of positive retained earnings. The company expanded its national market share to 4.1% by October 2025 and plans further growth with a new vape category launch and cultivation expansion at its Valleyfield facility. This performance underscores Cannara’s strategic focus on innovation and operational efficiency, positioning it for continued growth and value creation.

The most recent analyst rating on (TSE:LOVE) stock is a Buy with a C$2.00 price target. To see the full list of analyst forecasts on Cannara Biotech stock, see the TSE:LOVE Stock Forecast page.

Cannara Biotech to Release Financial Results and Mourns Board Member’s Passing

Cannara Biotech Inc. announced it will release its fiscal Q4 and full-year 2025 financial results on November 24, 2025. The announcement will be accompanied by an earnings webcast hosted by CEO Zohar Krivorot and CFO Nicholas Sosiak. Additionally, the company mourns the loss of Jack M. Kay, a valued board member with extensive leadership experience in the pharmaceutical and biotechnology sectors. His passing is a significant loss to the company and the broader industry.

The most recent analyst rating on (TSE:LOVE) stock is a Buy with a C$2.00 price target. To see the full list of analyst forecasts on Cannara Biotech stock, see the TSE:LOVE Stock Forecast page.